Osivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum “Universal” Influenza Vaccine in Japan KM Biologics, a Meiji Group company, has received an exclusive option to exercise an exclusive license for the development, manufacturing and commercialization of Osivax’s broad-spectrum “universal” influenza vaccine candidates in Japan Osivax is to receive upfront payment for execution …